CA3066689C - Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a - Google Patents

Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a Download PDF

Info

Publication number
CA3066689C
CA3066689C CA3066689A CA3066689A CA3066689C CA 3066689 C CA3066689 C CA 3066689C CA 3066689 A CA3066689 A CA 3066689A CA 3066689 A CA3066689 A CA 3066689A CA 3066689 C CA3066689 C CA 3066689C
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
human
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3066689A
Other languages
English (en)
Other versions
CA3066689A1 (fr
Inventor
Renfeng Guo
Niels R. Riedemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of CA3066689A1 publication Critical patent/CA3066689A1/fr
Application granted granted Critical
Publication of CA3066689C publication Critical patent/CA3066689C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La présente invention concerne des inhibiteurs de l'activité de C5a et leur utilisation dans le traitement de maladies cutanées, neutrophiles, inflammatoires chez un sujet.
CA3066689A 2017-06-23 2018-06-13 Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a Active CA3066689C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17177657 2017-06-23
EP17177657.8 2017-06-23
EP17189938.8 2017-09-07
EP17189938 2017-09-07
PCT/EP2018/065676 WO2018234118A1 (fr) 2017-06-23 2018-06-13 Traitement de maladies inflammatoires par des inhibiteurs de l'activité de c5a

Publications (2)

Publication Number Publication Date
CA3066689A1 CA3066689A1 (fr) 2018-12-27
CA3066689C true CA3066689C (fr) 2024-01-16

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066689A Active CA3066689C (fr) 2017-06-23 2018-06-13 Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a

Country Status (10)

Country Link
EP (1) EP3642230A1 (fr)
JP (1) JP7502865B2 (fr)
KR (1) KR20200020727A (fr)
CN (1) CN111201241A (fr)
AU (1) AU2018286754A1 (fr)
CA (1) CA3066689C (fr)
IL (1) IL271074A (fr)
SG (1) SG11201912882QA (fr)
TW (1) TWI786132B (fr)
WO (1) WO2018234118A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP7617012B2 (ja) * 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
PH12022552556A1 (en) * 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2021259160A1 (fr) * 2020-06-24 2021-12-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique c5a et leurs utilisations
CA3173944A1 (fr) 2021-01-13 2022-07-21 Visterra, Inc. Anticorps humanises anti-recepteur 1 du complement 5a et leurs methodes d'utilisation
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1991004014A1 (fr) 1989-09-21 1991-04-04 Synergen, Inc. Procede de transport de compositions a travers la barriere hemato-encephalique
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
HUE038239T2 (hu) 2004-02-12 2018-10-29 Archemix Llc Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok
SG151283A1 (en) * 2004-03-26 2009-04-30 Promics Pty Ltd Treatment of neurological conditions using complement c5a receptor modulators
CN101553244B (zh) 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
CA2940319A1 (fr) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibiteurs de c5a pour le traitement de la pneumonie virale
WO2016044419A1 (fr) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
WO2016061066A1 (fr) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Procedes de replication de culture cellulaire de production d'eculizumab a grande echelle
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
EP3313437A1 (fr) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. Procédé de traitement d'un patient soumis à une vaccination avec l'éculizumab ou un variant de l'éculizumab
EP3439658B1 (fr) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Antagonistes de c5ar solubles
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Also Published As

Publication number Publication date
CN111201241A (zh) 2020-05-26
EP3642230A1 (fr) 2020-04-29
KR20200020727A (ko) 2020-02-26
SG11201912882QA (en) 2020-01-30
JP2020524696A (ja) 2020-08-20
IL271074A (en) 2020-01-30
AU2018286754A1 (en) 2019-12-19
JP7502865B2 (ja) 2024-06-19
WO2018234118A1 (fr) 2018-12-27
CA3066689A1 (fr) 2018-12-27
TW201904611A (zh) 2019-02-01
TWI786132B (zh) 2022-12-11

Similar Documents

Publication Publication Date Title
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
CA3066689C (fr) Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
EP3220952B1 (fr) Méthode de traitement ou de prévention d'un accident vasculaire cérébral
JP7535591B2 (ja) コロナウイルス感染の処置のためのＣ５ａのインヒビター
ES2711882T3 (es) Método de tratamiento de la nefropatía diabética
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
US20240343787A1 (en) Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
AU2023229284A1 (en) Methods and compositions for treating and preventing fibrosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220824

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250605

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250605